What is Strata Critical Medical's operating income?

Strata Critical Medical's total operating income in 2025 was -$22.35 million, based on the following breakdown: Total Gross Profit: $41.13 million Total Operating Expenses: $63.48 million

Strata Critical Medical (SRTA) Financials

$5.13 -0.03 (-0.58%)

Closing price 07/9/2026 04:00 PM Eastern

Extended Trading

$5.14 +0.00 (+0.10%)

As of 07/9/2026 05:21 PM Eastern

Compare

Annual Income Statements for Strata Critical Medical

This table shows Strata Critical Medical's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2019	2020	2021	2022	2023	2024	2025
Period end date	9/30/2019	9/30/2020	9/30/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	21	13	-40	-27	-56	-27	41
Consolidated Net Income / (Loss)	-11	-10	-40	-27	-56	-27	41
Net Income / (Loss) Continuing Operations	21	13	-40	-27	-56	-16	-20
Total Pre-Tax Income	-11	-10	-44	-28	-58	-16	-20
Total Operating Income	-12	-10	-24	-54	-68	-23	-22
Total Gross Profit	31	23	11	22	42	30	41
Total Revenue	31	23	51	146	225	147	197
Operating Revenue	31	23	51	146	225	147	197
Total Cost of Revenue	0.00	0.00	40	124	183	117	156
Operating Cost of Revenue	-	-	40	124	183	117	156
Total Operating Expenses	11	10	35	76	110	52	63
Selling, General & Admin Expense	10	9.29	30	63	95	51	61
Amortization Expense	-	-	-	-	-	1.26	2.60
Total Other Income / (Expense), net	0.70	0.20	-20	25	11	6.36	2.29
Interest & Investment Income	-	-	0.00	-2.16	8.45	7.21	-0.95
Other Income / (Expense), net	0.00	0.00	-20	24	2.13	-0.85	3.24
Income Tax Expense	0.00	0.00	-3.64	-0.77	-1.47	0.00	0.00
Net Income / (Loss) Discontinued Operations	-	-	-	-	-	-11	61
Basic Earnings per Share	-	-	($0.93)	($0.38)	($0.76)	($0.35)	$0.50
Weighted Average Basic Shares Outstanding	25.14M	25.21M	42.88M	71.24M	73.52M	77.50M	82.09M
Diluted Earnings per Share	-	-	($0.93)	($0.38)	($0.76)	($0.35)	$0.50
Weighted Average Diluted Shares Outstanding	25.14M	25.21M	42.88M	71.24M	73.52M	77.50M	82.09M
Weighted Average Basic & Diluted Shares Outstanding	25.14M	25.21M	42.88M	72.04M	75.43M	79.69M	86.99M

This table shows Strata Critical Medical's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Income / (Loss) Attributable to Common Shareholders	0.29	-34	-4.23	-11	-1.95	-9.79	-3.49	-3.74	57	-8.83	2.15
Consolidated Net Income / (Loss)	0.29	-34	-4.23	-11	-1.95	-9.79	-3.49	-3.74	57	-8.83	2.15
Net Income / (Loss) Continuing Operations	0.29	-34	-4.23	-11	-5.63	-9.79	-1.61	-3.74	-9.66	-3.17	2.40
Total Pre-Tax Income	0.42	-35	-4.32	-11	-5.63	-9.90	-1.61	-3.72	-9.66	-3.18	2.40
Total Operating Income	-7.45	-36	-9.87	-12	-7.09	-8.37	-5.69	-4.95	-5.62	-4.19	-2.97
Total Gross Profit	16	9.01	10	16	7.51	13	7.05	18	12	-0.20	14
Total Revenue	71	47	52	68	36	54	36	71	49	23	67
Operating Revenue	71	47	52	68	36	54	36	71	49	23	67
Total Cost of Revenue	56	38	41	52	29	42	29	53	38	23	53
Operating Cost of Revenue	56	38	41	52	29	42	29	53	38	23	53
Total Operating Expenses	23	45	20	29	15	21	13	23	17	3.99	17
Selling, General & Admin Expense	19	41	17	25	14	19	12	20	16	7.12	16
Amortization Expense	-	-	-	-	-	-	0.41	-	-	-	1.49
Total Other Income / (Expense), net	7.87	0.67	5.55	0.88	1.47	-1.53	4.07	1.23	-4.04	1.02	5.38
Interest & Investment Income	2.15	4.32	2.07	1.79	1.76	3.66	1.32	1.16	-4.07	0.64	0.47
Other Income / (Expense), net	5.72	-1.70	3.48	-0.91	-0.30	-3.12	2.75	0.08	0.03	0.38	4.90
Income Tax Expense	0.13	-1.02	-0.08	0.05	0.00	-0.11	0.00	0.02	0.00	-0.00	0.00
Net Income / (Loss) Discontinued Operations	-	-	-	-	3.67	-	-1.88	-	67	-	-0.25
Basic Earnings per Share	$0.00	($0.45)	($0.06)	($0.15)	($0.03)	($0.11)	($0.04)	($0.05)	$0.70	($0.11)	$0.03
Weighted Average Basic Shares Outstanding	74.14M	73.52M	75.80M	77.60M	78.04M	77.50M	79.89M	81.30M	82.45M	82.09M	85.32M
Diluted Earnings per Share	$0.00	($0.45)	($0.06)	($0.15)	($0.03)	($0.11)	($0.04)	($0.05)	$0.70	($0.11)	$0.03
Weighted Average Diluted Shares Outstanding	81.01M	73.52M	75.80M	77.60M	78.04M	77.50M	79.89M	81.30M	82.45M	82.09M	90.17M
Weighted Average Basic & Diluted Shares Outstanding	74.63M	75.43M	77.35M	77.93M	78.31M	79.69M	81.02M	81.70M	86.37M	86.99M	86.53M

This table details how cash moves in and out of Strata Critical Medical's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2019	2020	2021	2022	2023	2024	2025
Period end date	9/30/2019	9/30/2020	9/30/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	-11	-10	-4.69	41	-15	-9.37	12
Net Cash From Operating Activities	-10	-11	-16	-37	-32	-2.52	-49
Net Cash From Continuing Operating Activities	-10	-11	-16	-37	-32	-2.52	-49
Net Income / (Loss) Continuing Operations	-11	-10	-40	-27	-56	-27	41
Consolidated Net Income / (Loss)	-11	-10	-40	-27	-56	-27	41
Depreciation Expense	0.47	0.53	0.60	5.73	7.11	5.96	8.19
Amortization Expense	-	-	0.00	-1.09	-6.52	-3.99	-2.21
Non-Cash Adjustments To Reconcile Net Income	0.32	0.50	30	-14	31	26	-89
Changes in Operating Assets and Liabilities, net	-0.25	-1.69	-5.84	-0.79	-8.20	-2.94	-7.14
Net Cash From Investing Activities	-1.05	-0.38	-321	79	17	-1.02	70
Net Cash From Continuing Investing Activities	-1.05	-0.38	-321	79	17	-1.02	70
Purchase of Property, Plant & Equipment	-0.60	-0.38	-0.80	-0.73	-2.11	-31	-9.60
Acquisitions	-0.45	0.00	-23	-48	-0.04	-4.35	-68
Purchase of Investments	0.00	0.00	-309	-228	-266	-143	-146
Sale and/or Maturity of Investments	0.00	0.00	11	356	285	177	296
Other Investing Activities, net	-	-	-	-	-	0.00	-2.81
Net Cash From Financing Activities	0.12	1.18	332	-1.08	-0.08	-5.76	-8.91
Net Cash From Continuing Financing Activities	0.12	1.18	332	-1.08	-0.08	-5.76	-8.91
Repurchase of Common Equity	-	-	-	-	0.00	-0.24	0.00
Other Financing Activities, net	0.12	0.02	214	-1.08	-0.08	-5.52	-8.91
Cash Income Taxes Paid	0.00	0.00	0.00	0.00	0.02	0.00	0.09

This table details how cash moves in and out of Strata Critical Medical's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Change in Cash & Equivalents	-1.12	-9.25	9.04	-9.69	-6.96	-1.76	16	25	-37	8.22	28
Net Cash From Operating Activities	2.02	-9.32	-16	8.43	6.36	-1.75	-0.25	-3.06	-37	-8.31	3.89
Net Cash From Continuing Operating Activities	2.02	-9.37	-16	8.39	6.36	-1.75	-0.25	-3.06	-37	-8.31	3.89
Net Income / (Loss) Continuing Operations	0.29	-34	-4.23	-11	-1.95	-9.79	-3.49	-3.74	57	-8.83	2.15
Consolidated Net Income / (Loss)	0.29	-34	-4.23	-11	-1.95	-9.79	-3.49	-3.74	57	-8.83	2.15
Depreciation Expense	1.84	1.81	1.59	1.56	1.28	1.53	1.70	1.78	1.70	3.01	3.06
Amortization Expense	-1.69	-1.80	-1.48	-0.82	-0.82	-0.87	-0.72	-0.79	-0.22	-0.48	-0.27
Non-Cash Adjustments To Reconcile Net Income	-2.22	25	0.87	12	5.55	7.27	1.47	5.57	-105	8.87	3.92
Changes in Operating Assets and Liabilities, net	3.80	-0.92	-12	6.65	2.30	0.11	0.81	-5.88	8.83	-11	-4.98
Net Cash From Investing Activities	-3.04	0.08	25	-17	-13	3.98	20	29	2.40	18	25
Net Cash From Continuing Investing Activities	-3.04	0.08	25	-17	-13	3.98	20	28	2.63	18	25
Purchase of Property, Plant & Equipment	-0.70	-0.02	-0.82	-16	-9.31	-4.58	-2.61	-2.53	-2.60	-1.85	-5.18
Acquisitions	-	-0.04	-0.31	-0.75	-2.83	-0.46	-0.53	-0.43	-65	-1.52	-0.30
Purchase of Investments	-136	-	-77	-	-66	-0.49	-84	-12	-50	-	0.00
Sale and/or Maturity of Investments	133	-	103	-	65	9.50	108	44	122	23	31
Other Investing Activities, net	-	-	-	-	-	-	0.00	-	-	-1.57	-0.29
Net Cash From Financing Activities	-0.01	-0.02	0.05	-1.21	-0.73	-3.87	-4.25	-1.14	-1.79	-1.74	-0.86
Net Cash From Continuing Financing Activities	-0.01	-0.02	0.05	-1.21	-0.73	-3.87	-4.25	-1.14	-1.79	-1.74	-0.86
Repayment of Debt	-	-	-	-	-	-	0.00	-	-	-	-0.33
Other Financing Activities, net	-0.01	-0.02	0.05	-0.96	-0.73	-3.87	-4.25	-1.14	-1.79	-1.74	-0.53
Effect of Exchange Rate Changes	-0.10	0.02	-0.03	-0.01	0.06	-0.11	0.13	-	-	-	0.00

This table presents Strata Critical Medical's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Total Assets	278	278	336	325	295	257	325
Total Current Assets	1.43	0.90	295	218	206	161	126
Cash & Equivalents	1.31	0.85	2.60	41	28	16	31
Restricted Cash	-	-	0.63	3.09	1.15	0.26	0.26
Short-Term Investments	-	-	279	151	138	109	30
Accounts Receivable	-	-	5.55	11	21	20	40
Prepaid Expenses	0.13	0.05	6.80	12	18	4.68	25
Plant, Property, & Equipment, net	0.00	0.00	2.05	2.04	2.90	28	36
Total Noncurrent Assets	276	277	39	105	86	67	163
Goodwill	-	-	13	39	40	16	88
Intangible Assets	-	-	24	46	21	7.96	48
Other Noncurrent Operating Assets	-	0.00	0.95	19	25	2.95	27
Total Liabilities & Shareholders' Equity	278	278	336	325	295	257	325
Total Liabilities	26	47	45	51	61	35	46
Total Current Liabilities	0.37	0.39	13	27	35	23	20
Accounts Payable	0.14	0.16	6.37	17	24	9.22	19
Other Current Liabilities	-	-	0.44	3.36	4.79	0.68	0.65
Total Noncurrent Liabilities	26	46	32	24	25	12	27
Noncurrent Deferred & Payable Income Tax Liabilities	-	-	0.14	1.88	0.45	0.00	0.35
Other Noncurrent Operating Liabilities	26	46	32	22	25	8.14	26
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	5.00	5.00	291	274	234	222	279
Total Preferred & Common Equity	5.00	5.00	291	274	234	222	279
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	5.00	5.00	291	274	234	222	279
Common Stock	2.67	23	369	376	390	407	425
Retained Earnings	2.33	-18	-76	-104	-160	-187	-146
Accumulated Other Comprehensive Income / (Loss)	-	-	-0.90	2.29	3.96	1.75	0.00

This table presents Strata Critical Medical's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026
Period end date	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025	9/30/2025	3/31/2026
Total Assets	318	283	280	283	251	258	335	328
Total Current Assets	209	194	183	172	152	156	122	124
Cash & Equivalents	37	37	26	20	35	59	23	59
Restricted Cash	1.46	1.30	2.06	1.38	0.86	1.56	0.26	0.26
Short-Term Investments	136	114	116	116	85	55	53	0.07
Accounts Receivable	21	24	28	24	22	28	38	40
Prepaid Expenses	13	18	11	9.56	9.32	13	8.76	25
Plant, Property, & Equipment, net	3.32	3.47	22	31	33	34	39	40
Total Noncurrent Assets	105	85	75	81	66	68	174	163
Goodwill	39	40	40	43	42	44	85	89
Intangible Assets	42	20	14	14	14	14	50	46
Other Noncurrent Operating Assets	24	26	22	24	10	9.91	40	28
Total Liabilities & Shareholders' Equity	318	283	280	283	251	258	335	328
Total Liabilities	55	46	51	49	31	35	52	42
Total Current Liabilities	30	23	30	27	22	26	28	21
Accounts Payable	19	11	17	16	11	14	27	20
Other Current Liabilities	4.76	4.43	4.15	4.47	3.36	3.52	0.65	0.99
Total Noncurrent Liabilities	24	23	21	22	8.94	8.51	24	21
Noncurrent Deferred & Payable Income Tax Liabilities	1.43	0.36	0.40	0.30	0.18	0.21	0.18	0.27
Other Noncurrent Operating Liabilities	23	23	20	22	8.76	8.30	24	21
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	263	237	229	233	220	223	283	286
Total Preferred & Common Equity	263	237	229	233	220	223	283	286
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	263	237	229	233	220	223	283	286
Common Stock	387	397	402	406	407	411	420	429
Retained Earnings	-126	-164	-175	-177	-190	-194	-137	-143
Accumulated Other Comprehensive Income / (Loss)	1.73	3.11	2.78	4.17	3.07	5.97	0.00	0.00

This table displays calculated financial ratios and metrics derived from Strata Critical Medical's official financial filings.

Metric	2019	2020	2021	2022	2023	2024	2025
Period end date	9/30/2019	9/30/2020	9/30/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
DEI Shares Outstanding	0.00	34,375,000.00	69,427,682.00	71,653,281.00	74,633,754.00	-	86,366,526.00
DEI Adjusted Shares Outstanding	0.00	34,375,000.00	69,427,682.00	71,653,281.00	74,633,754.00	-	86,366,526.00
DEI Earnings Per Adjusted Shares Outstanding	0.00	0.39	-0.58	-0.38	-0.75	-	0.48
Growth Metrics	-	-	-	-	-	-	-
Revenue Growth	0.00%	-24.88%	115.61%	189.20%	54.11%	10.44%	34.28%
EBITDA Growth	0.00%	11.17%	-342.99%	43.36%	-165.07%	49.84%	38.60%
EBIT Growth	0.00%	10.24%	-326.25%	33.63%	-125.20%	47.30%	18.24%
NOPAT Growth	0.00%	10.24%	-132.58%	-122.18%	-27.25%	50.19%	0.76%
Net Income Growth	0.00%	6.26%	-294.21%	31.94%	-105.71%	51.30%	251.42%
EPS Growth	0.00%	0.00%	0.00%	59.14%	-100.00%	53.95%	242.86%
Operating Cash Flow Growth	0.00%	-5.01%	-44.34%	-137.78%	12.88%	92.21%	-1,841.80%
Free Cash Flow Firm Growth	0.00%	0.00%	-634.86%	-49.96%	67.32%	-42.11%	-1,597.74%
Invested Capital Growth	0.00%	-79.82%	118.34%	825.41%	-15.52%	39.57%	254.53%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	0.00%	4.33%	2.84%	-26.32%
EBITDA Q/Q Growth	0.00%	0.00%	0.00%	0.00%	-46.75%	44.69%	31.29%
EBIT Q/Q Growth	0.00%	0.00%	0.00%	0.00%	-42.36%	42.63%	17.73%
NOPAT Q/Q Growth	0.00%	0.00%	0.00%	0.00%	-30.59%	44.55%	2.71%
Net Income Q/Q Growth	0.00%	0.00%	0.00%	0.00%	-49.34%	46.93%	2.38%
EPS Q/Q Growth	0.00%	0.00%	0.00%	0.00%	-52.00%	49.28%	0.00%
Operating Cash Flow Q/Q Growth	0.00%	0.00%	5.46%	-32.48%	-0.67%	75.03%	-15.47%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	1.08%	-35.19%
Invested Capital Q/Q Growth	0.00%	0.00%	0.00%	0.00%	-23.67%	-2.35%	5.20%
Profitability Metrics	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	20.82%	15.24%	18.71%	23.69%	20.86%
EBITDA Margin	-35.48%	-41.96%	-86.21%	-16.89%	-29.04%	-13.19%	-6.67%
Operating Margin	-37.00%	-44.21%	-47.68%	-36.63%	-30.25%	-13.64%	-11.34%
EBIT Margin	-37.00%	-44.21%	-87.39%	-20.05%	-29.31%	-13.98%	-9.69%
Profit (Net Income) Margin	-34.74%	-43.36%	-79.27%	-18.66%	-24.90%	-10.98%	20.97%
Tax Burden Percent	100.00%	100.00%	91.66%	97.25%	97.45%	99.07%	-206.06%
Interest Burden Percent	93.91%	98.08%	98.96%	95.66%	87.20%	79.26%	104.99%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	-85.26%	-65.17%	-29.58%	-11.22%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	-89.53%	-60.53%	-27.18%	-62.55%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	75.62%	43.12%	17.61%	27.72%
Return on Equity (ROE)	-4.31%	-4.21%	-15.33%	-9.63%	-22.04%	-11.97%	16.51%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	-841.92%	-246.25%	-48.34%	-62.62%	-123.22%
Operating Return on Assets (OROA)	-4.16%	-3.73%	-14.39%	-8.87%	-21.29%	-12.61%	-6.57%
Return on Assets (ROA)	-3.90%	-3.66%	-13.05%	-8.25%	-18.09%	-9.90%	14.21%
Return on Common Equity (ROCE)	-0.09%	-0.09%	-8.70%	-9.63%	-22.04%	-11.97%	16.51%
Return on Equity Simple (ROE_SIMPLE)	-216.76%	-203.20%	-13.75%	-9.93%	-23.93%	-12.30%	0.00%
Net Operating Profit after Tax (NOPAT)	-8.08	-7.25	-17	-37	-48	-24	-16
NOPAT Margin	-25.90%	-30.94%	-33.38%	-25.64%	-21.18%	-9.55%	-7.94%
Net Nonoperating Expense Percent (NNEP)	-0.99%	-1.05%	-8.27%	4.27%	-4.63%	-2.41%	51.33%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-20.35%	-10.70%	-5.61%
Cost of Revenue to Revenue	0.00%	0.00%	79.18%	84.76%	81.29%	76.31%	79.14%
SG&A Expenses to Revenue	33.58%	39.65%	59.66%	42.78%	42.27%	32.86%	30.88%
R&D to Revenue	2.41%	3.67%	3.33%	3.79%	2.05%	1.28%	0.00%
Operating Expenses to Revenue	35.99%	43.33%	68.50%	51.88%	48.96%	37.33%	32.20%
Earnings before Interest and Taxes (EBIT)	-12	-10	-44	-29	-66	-35	-19
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-11	-9.83	-44	-25	-65	-33	-13
Valuation Ratios	-	-	-	-	-	-	-
Price to Book Value (P/BV)	50.05	71.44	2.48	0.93	1.12	1.50	1.49
Price to Tangible Book Value (P/TBV)	50.05	71.44	2.85	1.36	1.52	1.99	2.90
Price to Revenue (P/Rev)	8.02	15.24	14.29	1.76	1.17	1.34	2.11
Price to Earnings (P/E)	12.11	26.50	0.00	0.00	0.00	0.00	10.05
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	8.26%	3.77%	0.00%	0.00%	0.00%	0.00%	9.95%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	51.24	0.77	1.44	2.19	1.63
Enterprise Value to Revenue (EV/Rev)	7.03	13.04	8.69	0.42	0.43	0.82	1.80
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	22.64	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-1.10	-1.15	-1.07	-0.84	-0.71	-0.65	-0.44
Leverage Ratio	1.10	1.15	1.17	1.17	1.22	1.21	1.16
Compound Leverage Factor	1.04	1.13	1.16	1.12	1.06	0.96	1.22
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	98.01%	97.84%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	1.99%	2.16%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	5.74	4.45	10.14	3.46	2.57	5.90	5.55
Noncontrolling Interest Sharing Ratio	98.01%	97.93%	43.27%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-
Current Ratio	3.85	2.29	23.07	8.20	5.81	7.07	6.38
Quick Ratio	3.52	2.17	22.49	7.63	5.27	6.54	5.11
Cash Flow Metrics	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	13	-72	-108	-35	-50	-172
Operating Cash Flow to CapEx	-1,705.63%	-2,869.50%	-1,949.44%	-5,086.30%	-1,641.25%	-8.16%	-509.79%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-
Asset Turnover	0.11	0.08	0.16	0.44	0.73	0.90	0.68
Accounts Receivable Turnover	0.00	0.00	0.00	17.79	14.13	11.68	6.60
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	0.00	71.59	91.24	14.71	6.07
Accounts Payable Turnover	0.00	0.00	12.26	10.81	9.06	10.36	11.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	20.51	25.84	31.26	55.34
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	29.78	33.75	40.27	35.22	33.18
Cash Conversion Cycle (CCC)	0.00	0.00	-29.78	-13.24	-14.43	-3.96	22.16
Capital & Investment Metrics	-	-	-	-	-	-	-
Invested Capital	-26	-47	8.57	79	67	94	218
Invested Capital Turnover	-1.20	-0.64	-2.65	3.32	3.08	3.10	1.41
Increase / (Decrease) in Invested Capital	0.00	-21	55	71	-12	27	156
Enterprise Value (EV)	219	305	439	61	96	204	354
Market Capitalization	250	357	722	257	263	333	415
Book Value per Share	$0.20	$0.15	$4.20	$3.83	$3.14	$2.83	$3.23
Tangible Book Value per Share	$0.20	$0.15	$3.65	$2.63	$2.32	$2.14	$1.66
Total Capital	252	231	291	274	234	222	279
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-278	-278	-283	-195	-167	-128	-61
Capital Expenditures (CapEx)	0.60	0.38	0.80	0.73	1.97	31	9.60
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-0.25	-0.34	-0.44	-3.64	3.49	9.61	45
Debt-free Net Working Capital (DFNWC)	1.06	0.51	282	192	171	138	106
Net Working Capital (NWC)	1.06	0.51	282	192	171	138	106
Net Nonoperating Expense (NNE)	2.76	2.91	23	-10	8.39	3.56	-57
Net Nonoperating Obligations (NNO)	-278	-278	-283	-195	-167	-128	-61
Total Depreciation and Amortization (D&A)	0.47	0.53	0.60	4.63	0.59	1.97	5.97
Debt-free, Cash-free Net Working Capital to Revenue	-0.79%	-1.45%	-0.86%	-2.49%	1.55%	3.87%	22.78%
Debt-free Net Working Capital to Revenue	3.40%	2.16%	558.45%	131.07%	75.84%	55.50%	53.97%
Net Working Capital to Revenue	3.40%	2.16%	558.45%	131.07%	75.84%	55.50%	53.97%
Earnings Adjustments	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.00	$0.00	($0.38)	($0.76)	($0.35)	$0.50
Adjusted Weighted Average Basic Shares Outstanding	0.00	0.00	42.88M	71.24M	73.52M	77.50M	82.09M
Adjusted Diluted Earnings per Share	$0.00	$0.00	$0.00	($0.38)	($0.76)	($0.35)	$0.50
Adjusted Weighted Average Diluted Shares Outstanding	0.00	0.00	42.88M	71.24M	73.52M	77.50M	82.09M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	0.00	42.88M	72.04M	75.43M	79.69M	86.99M
Normalized Net Operating Profit after Tax (NOPAT)	-8.08	-7.25	-17	-37	-48	-24	-16
Normalized NOPAT Margin	-25.90%	-30.94%	-33.38%	-25.64%	-21.18%	-9.55%	-7.94%
Pre Tax Income Margin	-34.74%	-43.36%	-86.48%	-19.18%	-25.55%	-11.08%	-10.18%
Debt Service Ratios	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	-0.89%	0.00%

This table displays calculated financial ratios and metrics derived from Strata Critical Medical's official financial filings.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
DEI Shares Outstanding	74,114,889.00	74,633,754.00	75,433,154.00	77,346,018.00	77,934,085.00	-	79,694,028.00	81,017,314.00	81,695,605.00	86,366,526.00	86,989,143.00
DEI Adjusted Shares Outstanding	74,114,889.00	74,633,754.00	75,433,154.00	77,346,018.00	77,934,085.00	-	79,694,028.00	81,017,314.00	81,695,605.00	86,366,526.00	86,989,143.00
DEI Earnings Per Adjusted Shares Outstanding	0.00	-0.45	-0.06	-0.15	-0.03	-	-0.04	-0.05	0.70	-0.10	0.02
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	56.25%	24.50%	13.79%	11.41%	-49.52%	14.49%	-30.22%	4.20%	36.70%	361.21%	87.45%
EBITDA Growth	82.22%	-126.33%	47.67%	15.04%	-339.48%	70.99%	68.79%	68.46%	40.75%	-131.23%	341.14%
EBIT Growth	82.72%	-110.98%	47.88%	10.97%	-327.47%	69.23%	54.10%	62.66%	24.38%	-210.01%	165.77%
NOPAT Growth	29.46%	-81.08%	23.07%	0.49%	3.59%	76.50%	42.39%	59.22%	20.73%	-144.87%	25.27%
Net Income Growth	103.13%	-120.18%	58.46%	7.41%	-776.12%	71.15%	17.50%	66.95%	3,038.38%	9.80%	161.67%
EPS Growth	100.00%	-136.84%	57.14%	11.76%	0.00%	75.56%	33.33%	66.67%	2,433.33%	0.00%	175.00%
Operating Cash Flow Growth	131.85%	-2.37%	7.74%	202.83%	214.14%	81.20%	98.42%	-136.35%	-686.89%	-374.14%	1,679.27%
Free Cash Flow Firm Growth	88.67%	0.00%	99.49%	91.67%	7.48%	-156.33%	-3,936.96%	-399.91%	-787.92%	-1,405.80%	-606.43%
Invested Capital Growth	11.20%	-15.52%	-7.10%	-3.68%	9.09%	39.57%	17.23%	26.63%	115.92%	254.53%	129.27%
Revenue Q/Q Growth	17.14%	-33.54%	8.50%	31.90%	-46.92%	-27.40%	513.01%	30.37%	-30.37%	-53.88%	196.38%
EBITDA Q/Q Growth	89.12%	-2,265.53%	83.18%	-96.26%	43.70%	-220.36%	-147.46%	-0.75%	-5.74%	68.63%	466.49%
EBIT Q/Q Growth	88.21%	-2,059.11%	82.88%	-104.41%	43.42%	-199.48%	-184.57%	-0.95%	-14.60%	31.74%	150.56%
NOPAT Q/Q Growth	39.75%	-384.38%	72.31%	-23.12%	41.62%	-136.70%	-160.83%	34.67%	-13.48%	25.40%	-1.30%
Net Income Q/Q Growth	102.36%	-11,844.29%	87.53%	-167.50%	82.75%	-401.18%	64.33%	-7.16%	1,633.96%	-115.38%	124.39%
EPS Q/Q Growth	100.00%	0.00%	86.67%	-150.00%	80.00%	-266.67%	63.64%	-25.00%	1,500.00%	-115.71%	127.27%
Operating Cash Flow Q/Q Growth	124.68%	-560.70%	-66.86%	154.20%	-24.61%	-127.57%	85.96%	-1,145.53%	-1,117.27%	77.73%	146.77%
Free Cash Flow Firm Q/Q Growth	77.77%	9.74%	96.37%	-1,043.11%	-147.00%	-209.56%	-251.91%	-32.08%	-338.71%	-38.42%	17.82%
Invested Capital Q/Q Growth	-0.95%	-23.67%	25.84%	1.24%	12.19%	-2.35%	61.10%	9.35%	91.29%	5.20%	4.18%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	21.81%	18.98%	19.68%	24.07%	20.82%	23.16%	19.62%	25.05%	23.56%	-0.89%	20.95%
EBITDA Margin	-2.21%	-78.62%	-12.19%	-18.13%	-19.23%	-19.92%	-5.45%	-5.49%	-8.34%	-5.67%	7.01%
Operating Margin	-10.43%	-75.05%	-19.16%	-17.88%	-19.67%	-15.40%	-15.81%	-7.00%	-11.40%	-18.45%	-4.41%
EBIT Margin	-2.42%	-78.63%	-12.40%	-19.22%	-20.50%	-21.13%	-8.16%	-6.89%	-11.34%	-16.78%	2.86%
Profit (Net Income) Margin	0.40%	-71.49%	-8.22%	-16.67%	-5.42%	-18.02%	-9.72%	-5.29%	116.47%	-38.85%	3.20%
Tax Burden Percent	69.14%	97.07%	98.05%	100.46%	34.73%	98.94%	216.69%	100.56%	-594.55%	278.03%	89.68%
Interest Burden Percent	-24.18%	93.66%	67.57%	86.31%	76.13%	86.16%	54.96%	76.32%	172.79%	83.28%	124.52%
Effective Tax Rate	30.86%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-18.66%	-161.68%	-35.44%	-34.29%	-30.44%	-33.40%	-15.86%	-12.88%	-14.12%	-18.25%	-6.20%
ROIC Less NNEP Spread (ROIC-NNEP)	-21.53%	-156.71%	-37.05%	-32.51%	-32.37%	-30.74%	-16.22%	-12.66%	-71.48%	-12.94%	-11.90%
Return on Net Nonoperating Assets (RNNOA)	14.95%	111.64%	24.25%	20.97%	20.40%	19.92%	9.71%	7.25%	29.60%	5.74%	4.24%
Return on Equity (ROE)	-3.71%	-50.04%	-11.19%	-13.33%	-10.05%	-13.48%	-6.15%	-5.63%	15.49%	-12.52%	-1.96%
Cash Return on Invested Capital (CROIC)	0.00%	-48.34%	-44.73%	-48.62%	-58.07%	-62.62%	-29.88%	-41.19%	-84.02%	-123.22%	-86.97%
Operating Return on Assets (OROA)	-1.62%	-57.12%	-9.49%	-15.26%	-13.86%	-19.06%	-4.02%	-6.51%	-9.82%	-11.36%	2.26%
Return on Assets (ROA)	0.27%	-51.93%	-6.29%	-13.23%	-3.66%	-16.25%	-4.78%	-5.00%	100.85%	-26.31%	2.53%
Return on Common Equity (ROCE)	-3.71%	-50.04%	-11.19%	-13.33%	-10.05%	-13.48%	-6.15%	-5.63%	15.49%	-12.52%	-1.96%
Return on Equity Simple (ROE_SIMPLE)	-14.28%	0.00%	-21.18%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-5.15	-25	-6.91	-8.50	-4.96	-5.86	-3.98	-3.47	-3.94	-2.94	-2.97
NOPAT Margin	-7.21%	-52.54%	-13.41%	-12.52%	-13.77%	-10.78%	-11.07%	-4.90%	-7.98%	-12.91%	-4.41%
Net Nonoperating Expense Percent (NNEP)	2.87%	-4.97%	1.61%	-1.79%	1.92%	-2.66%	0.36%	-0.21%	57.37%	-5.31%	5.70%
Return On Investment Capital (ROIC_SIMPLE)	-	-10.65%	-2.92%	-3.71%	-2.13%	-2.64%	-1.81%	-1.55%	-1.39%	-1.05%	-1.04%
Cost of Revenue to Revenue	78.19%	81.02%	80.32%	75.93%	79.18%	76.84%	80.38%	74.95%	76.44%	100.89%	79.05%
SG&A Expenses to Revenue	26.97%	86.87%	33.41%	36.99%	38.46%	34.87%	34.30%	28.45%	33.07%	31.31%	23.16%
R&D to Revenue	1.51%	2.08%	1.30%	1.43%	1.16%	1.37%	0.00%	1.29%	0.92%	0.00%	0.00%
Operating Expenses to Revenue	32.23%	94.03%	38.84%	41.95%	40.49%	38.56%	35.43%	32.05%	34.96%	17.55%	25.36%
Earnings before Interest and Taxes (EBIT)	-1.73	-37	-6.39	-13	-7.39	-11	-2.93	-4.88	-5.59	-3.82	1.93
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-1.58	-37	-6.28	-12	-6.94	-11	-1.96	-3.89	-4.11	-1.29	4.72
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.73	1.12	0.91	1.17	0.98	1.50	0.99	1.46	1.46	1.49	1.27
Price to Tangible Book Value (P/TBV)	1.05	1.52	1.21	1.53	1.30	1.99	1.33	1.98	2.78	2.90	2.41
Price to Revenue (P/Rev)	0.89	1.17	0.93	1.13	1.13	1.34	1.66	1.28	1.54	2.11	1.59
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	10.24	10.05	7.74
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	9.77%	9.95%	12.92%
Enterprise Value to Invested Capital (EV/IC)	0.19	1.44	0.74	1.47	0.95	2.19	0.98	1.96	1.63	1.63	1.34
Enterprise Value to Revenue (EV/Rev)	0.08	0.43	0.27	0.53	0.45	0.82	0.74	0.83	1.26	1.80	1.33
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	7.56	163.59	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.69	-0.71	-0.65	-0.65	-0.63	-0.65	-0.60	-0.57	-0.41	-0.44	-0.36
Leverage Ratio	1.18	1.22	1.19	1.23	1.21	1.21	1.17	1.19	1.20	1.16	1.14
Compound Leverage Factor	-0.29	1.14	0.81	1.06	0.92	1.04	0.64	0.91	2.07	0.97	1.42
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	2.89	2.89	3.45	3.65	3.15	6.20	4.28	6.10	5.27	5.71	5.69
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	6.87	5.81	8.35	6.04	6.32	7.07	6.96	5.95	4.39	6.38	5.93
Quick Ratio	6.40	5.27	7.51	5.60	5.92	6.54	6.50	5.38	4.07	5.11	4.70
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-14	-13	-0.46	-5.24	-13	-32	-19	-26	-115	-159	-131
Operating Cash Flow to CapEx	291.08%	0.00%	-1,905.76%	52.15%	68.28%	-38.29%	-9.41%	-124.10%	-1,437.26%	-449.51%	75.01%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.67	0.73	0.76	0.79	0.68	0.90	0.49	0.95	0.87	0.68	0.79
Accounts Receivable Turnover	13.36	14.13	11.57	9.49	8.92	11.68	5.75	9.10	8.63	6.60	7.41
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	77.89	91.24	78.28	19.07	11.99	14.71	7.28	9.12	7.74	6.07	6.29
Accounts Payable Turnover	11.72	9.06	16.77	11.80	9.20	10.36	9.82	12.58	9.31	11.00	11.84
Days Sales Outstanding (DSO)	27.32	25.84	31.55	38.47	40.92	31.26	63.51	40.11	42.30	55.34	49.29
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	31.14	40.27	21.77	30.94	39.69	35.22	37.18	29.01	39.20	33.18	30.82
Cash Conversion Cycle (CCC)	-3.82	-14.43	9.78	7.53	1.23	-3.96	26.33	11.09	3.10	22.16	18.47
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	88	67	84	85	96	94	99	108	207	218	227
Invested Capital Turnover	2.59	3.08	2.64	2.74	2.21	3.10	1.43	2.63	1.77	1.41	1.40
Increase / (Decrease) in Invested Capital	8.85	-12	-6.45	-3.26	7.98	27	15	23	111	156	128
Enterprise Value (EV)	17	96	63	125	91	204	97	212	337	354	305
Market Capitalization	192	263	215	269	229	333	218	326	413	415	364
Book Value per Share	$3.55	$3.14	$3.14	$2.97	$3.00	$2.83	$2.76	$2.75	$3.46	$3.23	$3.28
Tangible Book Value per Share	$2.46	$2.32	$2.35	$2.28	$2.27	$2.14	$2.06	$2.04	$1.82	$1.66	$1.73
Total Capital	263	234	237	229	233	222	220	223	283	279	286
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-175	-167	-152	-144	-138	-128	-121	-115	-76	-61	-59
Capital Expenditures (CapEx)	0.70	-0.11	0.82	16	9.31	4.58	2.61	2.47	2.60	1.85	5.18
Debt-free, Cash-free Net Working Capital (DFCFNWC)	3.69	3.49	18	8.62	6.86	9.61	9.57	15	18	45	44
Debt-free Net Working Capital (DFNWC)	178	171	171	153	145	138	130	130	95	106	103
Net Working Capital (NWC)	178	171	171	153	145	138	130	130	95	106	103
Net Nonoperating Expense (NNE)	-5.44	9.00	-2.67	2.82	-3.01	3.93	-0.49	0.28	-61	5.90	-5.13
Net Nonoperating Obligations (NNO)	-175	-167	-152	-144	-138	-128	-121	-115	-76	-61	-59
Total Depreciation and Amortization (D&A)	0.15	0.00	0.11	0.74	0.46	0.66	0.97	0.99	1.48	2.53	2.80
Debt-free, Cash-free Net Working Capital to Revenue	1.71%	1.55%	7.99%	3.61%	3.38%	3.87%	7.29%	5.97%	6.89%	22.78%	19.32%
Debt-free Net Working Capital to Revenue	82.64%	75.84%	73.79%	64.03%	71.22%	55.50%	99.38%	51.18%	35.36%	53.97%	45.15%
Net Working Capital to Revenue	82.64%	75.84%	73.79%	64.03%	71.22%	55.50%	99.38%	51.18%	35.36%	53.97%	45.15%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	($0.45)	($0.06)	($0.15)	($0.03)	($0.11)	($0.04)	($0.05)	$0.70	($0.11)	$0.03
Adjusted Weighted Average Basic Shares Outstanding	74.14M	73.52M	75.80M	77.60M	78.04M	77.50M	79.89M	81.30M	82.45M	82.09M	85.32M
Adjusted Diluted Earnings per Share	$0.00	($0.45)	($0.06)	($0.15)	($0.03)	($0.11)	($0.04)	($0.05)	$0.70	($0.11)	$0.03
Adjusted Weighted Average Diluted Shares Outstanding	81.01M	73.52M	75.80M	77.60M	78.04M	77.50M	79.89M	81.30M	82.45M	82.09M	90.17M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	74.63M	75.43M	77.35M	77.93M	78.31M	79.69M	81.02M	81.70M	86.37M	86.99M	86.53M
Normalized Net Operating Profit after Tax (NOPAT)	-5.15	-25	-6.91	-8.50	-4.96	-5.86	-3.98	-3.47	-3.94	-2.94	-2.08
Normalized NOPAT Margin	-7.21%	-52.54%	-13.41%	-12.52%	-13.77%	-10.78%	-11.07%	-4.90%	-7.98%	-12.91%	-3.09%
Pre Tax Income Margin	0.59%	-73.64%	-8.38%	-16.59%	-15.60%	-18.21%	-4.48%	-5.26%	-19.59%	-13.97%	3.56%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	-0.50%	-0.47%	-0.89%	0.00%	0.00%	0.00%	0.00%	0.00%

Financials Breakdown Chart

Key Financial Trends

Blade Air Mobility (NASDAQ: BLDE) showed a noticeably stronger first quarter in 2026, with revenue growth, a return to profitability, and a much healthier cash position. Still, the latest results also show that the business remains volatile, with operating losses, heavy working-capital swings, and a balance sheet that has been reshaped by acquisitions and investment activity over the last year.

Revenue rebounded sharply in Q1 2026. Operating revenue rose to $67.4 million from $35.9 million in Q1 2025, nearly doubling year over year.
The company returned to a profit in Q1 2026. Blade reported $2.15 million in net income, compared with a $3.49 million loss in the prior-year quarter.
Operating cash flow improved meaningfully. Net cash from operating activities reached $3.9 million in Q1 2026, versus a small outflow of $246,000 in Q1 2025.
Cash and investments were boosted significantly. Cash and equivalents increased to $58.7 million at March 31, 2026, and the company also held short-term investments and continued to generate cash from investment sales.
Gross profit expanded with sales growth. Gross profit reached $14.1 million in Q1 2026, up from $7.1 million a year earlier.
Balance sheet equity remains substantial. Total common equity was $285.7 million, providing a meaningful book-value cushion.
Investing cash flow was unusually strong. Blade generated $24.7 million of net cash from investing activities in Q1 2026, largely because it sold $30.5 million of investments. That helped cash, but it is not the same as recurring operating cash generation.
Depreciation and amortization remain meaningful. These non-cash charges continue to affect reported earnings and reflect an asset-heavy, acquisition-influenced business model.
Share count has drifted higher over time. Weighted average diluted shares were 90.2 million in Q1 2026 versus 79.9 million in Q1 2025, which can dilute per-share results.
Operating margin is still negative. Even with stronger revenue, Blade posted an operating loss of $3.0 million in Q1 2026.
Working capital pressure remains a concern. Changes in operating assets and liabilities used $5.0 million of cash in Q1 2026, showing the business can still be cash-intensive quarter to quarter.
Quarterly performance has been volatile. Over the last several quarters, Blade’s results swung from losses to a large Q3 2025 profit tied to discontinued operations, then back to a Q4 2025 loss before the latest rebound.
Recent history shows recurring operating losses. In 2024 and much of 2025, the company repeatedly posted negative operating income, suggesting the core business still has work to do before consistent profitability.
Heavy acquisition activity has reshaped the balance sheet. Goodwill and intangible assets remain large, which can create future impairment risk if acquired businesses underperform.

Bottom line: Blade Air Mobility’s latest quarter looks like a step in the right direction, especially on revenue, earnings, and operating cash flow. However, investors should keep an eye on whether the improvement is sustainable without relying on investment sales or one-time items, since the core operating business is still working toward consistent profitability.

07/10/26 02:56 AM ETAI Generated. May Contain Errors.

Strata Critical Medical Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Strata Critical Medical's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Strata Critical Medical's net income appears to be on a downward trend, with a most recent value of $41.35 million in 2025, falling from -$10.84 million in 2019. The previous period was -$27.31 million in 2024. See Strata Critical Medical's forecast for analyst expectations on what's next for the company.

Strata Critical Medical's total operating income in 2025 was -$22.35 million, based on the following breakdown:

Total Gross Profit: $41.13 million
Total Operating Expenses: $63.48 million

Over the last 6 years, Strata Critical Medical's total revenue changed from $31.20 million in 2019 to $197.14 million in 2025, a change of 531.9%.

Strata Critical Medical's total liabilities were at $46.40 million at the end of 2025, a 33.6% increase from 2024, and a 77.7% increase since 2019.

In the past 6 years, Strata Critical Medical's cash and equivalents has ranged from $846.07 thousand in 2020 to $41.34 million in 2022, and is currently $30.97 million as of their latest financial filing in 2025.

Over the last 6 years, Strata Critical Medical's book value per share changed from 0.20 in 2019 to 3.23 in 2025, a change of 1,524.6%.

Related Companies

Financial statements for NASDAQ:SRTA last updated on 7/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Strata Critical Medical (SRTA) Financials

Financials Breakdown Chart

Key Financial Trends

Strata Critical Medical Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Strata Critical Medical (SRTA) Financials

Annual Income Statements for Strata Critical Medical

Quarterly Income Statements for Strata Critical Medical

Annual Cash Flow Statements for Strata Critical Medical

Quarterly Cash Flow Statements for Strata Critical Medical

Annual Balance Sheets for Strata Critical Medical

Quarterly Balance Sheets for Strata Critical Medical

Annual Metrics And Ratios for Strata Critical Medical

Quarterly Metrics And Ratios for Strata Critical Medical

Financials Breakdown Chart

Key Financial Trends

Strata Critical Medical Financials - Frequently Asked Questions

When does Strata Critical Medical's fiscal year end?

How has Strata Critical Medical's net income changed over the last 6 years?

What is Strata Critical Medical's operating income?

How has Strata Critical Medical's revenue changed over the last 6 years?

How much debt does Strata Critical Medical have?

How much cash does Strata Critical Medical have?

How has Strata Critical Medical's book value per share changed over the last 6 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools